• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Diisopropylfluorophosphate increases clofibric acid clearance: supporting evidence for a futile cycle.

作者信息

Rowe B J, Meffin P J

出版信息

J Pharmacol Exp Ther. 1984 Jul;230(1):237-41.

PMID:6747828
Abstract

Clofibric acid has been shown previously to undergo a futile cycle in which its net clearance is dependent upon conjugation to form an acyl (ester) glucuronide and a combination of hydrolysis of the conjugate and its renal clearance. If hydrolysis is mediated by esterases then inhibition of these enzymes should increase clofibric acid clearance. Plasma clofibric acid clearance was measured in a group of six rabbits both while conscious and then while anesthetized and treated with diisopropylfluorophosphate (DFP). Clofibric acid clearance also was determined in a control group of six rabbits both while conscious and subsequently while anesthetized. Plasma clearances of unbound and total clofibric acid (protein bound plus unbound) were similar in both groups while conscious but increased 2-fold in DFP-treated compared with conscious animals (P less than .001) and were 3-fold greater in DFP-treated animals than in control, anesthetized animals (P less than .001). These data support the futile cycle for clofibric and implicate esterases in the in vivo hydrolysis of clofibric acid glucuronide.

摘要

相似文献

1
Diisopropylfluorophosphate increases clofibric acid clearance: supporting evidence for a futile cycle.
J Pharmacol Exp Ther. 1984 Jul;230(1):237-41.
2
Reduced clofibric acid clearance in renal dysfunction is due to a futile cycle.肾功能不全时氯贝酸清除率降低是由于无效循环所致。
J Pharmacol Exp Ther. 1983 Dec;227(3):732-8.
3
A renal mechanism for the clofibric acid-probenecid interaction.
J Pharmacol Exp Ther. 1983 Dec;227(3):739-42.
4
The analysis of [14C]clofibric acid glucuronide and [14C]clofibric acid in plasma and urine using high-performance liquid chromatography.
J Chromatogr. 1983 Nov 11;278(1):101-8. doi: 10.1016/s0378-4347(00)84760-x.
5
Effect of renal dysfunction on the individual components of the acyl-glucuronide futile cycle.
J Pharmacol Exp Ther. 1989 Oct;251(1):288-94.
6
Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man.实验动物和人类中氯贝酸及氯贝特代谢性结合的种属差异。
Drug Metab Dispos. 1983 Mar-Apr;11(2):97-102.
7
Effect of esterase inhibition on the disposition of zomepirac glucuronide and its covalent binding to plasma proteins in the guinea pig.酯酶抑制对唑美昔康葡萄糖醛酸苷在豚鼠体内的处置及其与血浆蛋白共价结合的影响。
J Pharmacol Exp Ther. 1990 Jan;252(1):218-24.
8
Predictions of stability in pharmaceutical preparations XIX: Stability evaluation and bioanalysis of clofibric acid esters by high-pressure liquid chromatography.药物制剂稳定性预测XIX:用高压液相色谱法对氯贝酸酯进行稳定性评估和生物分析
J Pharm Sci. 1982 Jan;71(1):14-25. doi: 10.1002/jps.2600710105.
9
Simultaneous GLC determination of clofibrate and clofibric acid in human plasma.气相色谱法同时测定人血浆中氯贝丁酯和氯贝酸
J Pharm Sci. 1980 Jan;69(1):92-3. doi: 10.1002/jps.2600690126.
10
Bioavailability studies of etofibrate in rhesus monkeys.益多酯在恒河猴体内的生物利用度研究。
Arzneimittelforschung. 1985;35(2):489-92.

引用本文的文献

1
Human α/β hydrolase domain containing 10 (ABHD10) is responsible enzyme for deglucuronidation of mycophenolic acid acyl-glucuronide in liver.人α/β 水解酶结构域包含 10 (ABHD10)是负责酶去葡糖醛酸化麦考酚酸酰 - 葡糖醛酸在肝脏。
J Biol Chem. 2012 Mar 16;287(12):9240-9. doi: 10.1074/jbc.M111.271288. Epub 2012 Jan 31.
2
The role of beta-glucuronidase in drug disposition and drug targeting in humans.β-葡萄糖醛酸酶在人体药物处置和药物靶向中的作用。
Clin Pharmacokinet. 1997 Jul;33(1):18-31. doi: 10.2165/00003088-199733010-00003.
3
Glucuronidation of drugs. A re-evaluation of the pharmacological significance of the conjugates and modulating factors.
Clin Pharmacokinet. 1992 Oct;23(4):292-310. doi: 10.2165/00003088-199223040-00005.